WASHINGTON (AP) โ The U.S. has approved the worldโs only twice-a-year shot to prevent HIV, maker Gilead Sciences announced Wednesday. It’s the first step in an anticipated global rollout that could protect millions โ although it’s unclear how many in the U.S. and abroadย will get accessย to the powerful new option.
While a vaccine to prevent HIV still is needed, some experts say the shot โ a drug called lenacapvir โ could be the next best thing. It nearlyย eliminated new infectionsย in two groundbreaking studies of peopleย at high risk, better than daily preventive pills they can forget to take.
โThis really has the possibility of ending HIV transmission,โ said Greg Millett, public policy director at amfAR, The Foundation for AIDS Research.
Condoms help guard against HIV infection if used properly but what’s called PrEP โ regularly using preventive medicines such as the daily pills or a different shot given every two months โ is increasingly important. Lenacapavir’s six-month protection makes it the longest-lasting type, an option that could attract people wary of more frequent doctor visits or stigma from daily pills.
But upheaval in U.S. healthcare โย including cuts to public healthย agencies andย Medicaidย โ and slashing of Americanย foreign aid to fight HIVย are clouding the prospects.
Millett said “gaping holes in the system” in the U.S. and globally “are going to make it difficult for us to make sure we not only get lenacapavir into peopleโs bodies but make sure they come backโ even as little as twice a year.
Gileadโs drug already is sold to treat HIV under the brand name Sunlenca. The prevention dose will be sold under a different name, Yeztugo. Itโs given as two injections under the skin of the abdomen, leaving a small โdepotโ of medication to slowly absorb into the body.
Gilead didn’t immediately announce its price. The drug only prevents HIV transmission โ it doesnโt block other sexually transmitted diseases.
Global efforts at ending the HIV pandemic by 2030 have stalled. There still are more than 30,000 new infections in the U.S. each year and about 1.3 million worldwide.
Only about 400,000 Americans already use some form of PrEP, a fraction of those estimated to benefit. A recent study found states with high use of PrEP saw a decrease in HIV infections, while rates continued rising elsewhere.
About half of new infections are in women, who often need protection they can use without a partner’s knowledge or consent. One rigorous study in South Africa and Uganda compared more than 5,300 sexually active young women and teen girls given twice-yearly lenacapavir or the daily pills. There were no HIV infections in those receiving the shot while about 2% in the comparison group caught HIV from infected sex partners.
A second study found the twice-yearly shot nearly as effective in gay men and gender-nonconforming people in the U.S. and in several other countries hard-hit by HIV.
Ian Haddock of Houston had tried PrEP off and on since 2015 but he jumped at the chance to participate in the lenacapavir study and continues with the twice-yearly shots as part of the research follow-up.
โNow I forget that Iโm on PrEP because I donโt have to carry around a pill bottle,โ said Haddock, who leads the Normal Anomaly Initiative, a nonprofit serving Black LGBTQ+ communities.
โMen, women, gay, straight โ it really just kinds of expands the opportunity for prevention,โ he added. Just remembering a clinic visit every six months โis a powerful tool versus constantly having to talk about, like, condoms, constantly making sure youโre taking your pill every day.โ
โEveryone in every country whoโs at risk of HIV needs access to PrEP,โ added Dr. Gordon Crofoot of Houston, who helped lead the study in men. โWe need to get easier access to PrEP thatโs highly effective like this is.โ
